| Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies P Tarantino, R Carmagnani Pestana, C Corti, S Modi, A Bardia, ... CA: A Cancer Journal for Clinicians, 2021 | 290 | 2021 |
| PTEN Alterations and Their Role in Cancer Management: Are We Making Headway on Precision Medicine? N Fusco, E Sajjadi, K Venetis, G Gaudioso, G Lopez, C Corti, EG Rocco, ... Genes 11 (7), 719, 2020 | 133 | 2020 |
| Combining antibody-drug conjugates with immunotherapy in solid tumors: current landscape and future perspectives E Nicolò, F Giugliano, L Ascione, P Tarantino, C Corti, SM Tolaney, ... Cancer Treatment Reviews 106, 102395, 2022 | 111 | 2022 |
| HER2 low, ultra-low, and novel complementary biomarkers: expanding the spectrum of HER2 positivity in breast cancer K Venetis, E Crimini, E Sajjadi, C Corti, E Guerini-Rocco, G Viale, ... Frontiers in Molecular Biosciences, 2022 | 106 | 2022 |
| Immunotherapy for early triple negative breast cancer: research agenda for the next decade P Tarantino, C Corti, P Schmid, J Cortes, EA Mittendorf, H Rugo, ... NPJ Breast Cancer 8 (1), 23, 2022 | 104 | 2022 |
| Bystander effect of antibody-drug conjugates: fact or fiction? F Giugliano, C Corti, P Tarantino, F Michelini, C G Current Oncology Reports, 2022 | 88 | 2022 |
| Mismatch repair protein loss as a prognostic and predictive biomarker in breast cancers regardless of microsatellite instability N Fusco, G Lopez, C Corti, C Pesenti, P Colapietro, G Ercoli, G Gaudioso, ... JNCI Cancer Spectrum 2 (4), pky056, 2018 | 83 | 2018 |
| Therapeutic vaccines for breast cancer: Has the time finally come? C Corti, PPMB Giachetti, AMM Eggermont, S Delaloge, G Curigliano European Journal of Cancer 160, 150-174, 2022 | 80 | 2022 |
| Seroconversion rate after vaccination against COVID-19 in patients with cancer -a systematic review C Corti, G Antonarelli, F Scotté, JP Spano, J Barrière, JM Michot, F André, ... Annals of Oncology, 2021 | 77 | 2021 |
| Targeting brain metastases in breast cancer C Corti, G Antonarelli, C Criscitiello, N Lin U, J Cortes, P Poortmans, ... Cancer Treatment Reviews 103 (102324), 2021 | 76 | 2021 |
| SARS-CoV-2 vaccines for cancer patients: a call to action C Corti, E Crimini, P Tarantino, G Pravettoni, AMM Eggermont, S Delaloge, ... European Journal of Cancer 148, 316-327, 2021 | 73 | 2021 |
| Antibody–Drug Conjugates for the Treatment of Breast Cancer C Corti, F Giugliano, E Nicolò, L Ascione, G Curigliano Cancers 13 (12), 2021 | 67 | 2021 |
| Artificial intelligence in cancer research and precision medicine: Applications, limitations and priorities to drive transformation in the delivery of equitable and unbiased care C Corti, M Cobanaj, EC Dee, C Criscitiello, SM Tolaney, LA Celi, ... Cancer Treatment Reviews, 102498, 2023 | 63 | 2023 |
| Sex-based differences in response to anti-PD-1 or PD-L1 treatment in patients with non-small-cell lung cancer expressing high PD-L1 levels. A systematic review and meta … F Conforti, L Pala, E Pagan, C Corti, V Bagnardi, P Queirolo, C Catania, ... ESMO open 6 (5), 100251, 2021 | 63 | 2021 |
| Therapeutic cancer vaccines revamping: technology advancements and pitfalls G Antonarelli, C Corti, P Tarantino, L Ascione, J Cortes, P Romero, ... Annals of Oncology 32 (12), 1537-1551, 2021 | 62 | 2021 |
| CAR-T cell therapy for triple-negative breast cancer and other solid tumors: preclinical and clinical progress C Corti, K Venetis, E Sajjadi, L Zattoni, G Curigliano, N Fusco Expert Opinion on Investigational Drugs 31 (6), 593-605, 2022 | 58 | 2022 |
| Commentary: SARS-CoV-2 vaccines and cancer patients C Corti, G Curigliano Annals of Oncology, 2021 | 55 | 2021 |
| Lymphovascular invasion and extranodal tumour extension are risk indicators of breast cancer related lymphoedema: an observational retrospective study with long-term follow-up M Invernizzi, C Corti, G Lopez, A Michelotti, L Despini, D Gambini, ... BMC cancer 18, 1-12, 2018 | 45 | 2018 |
| Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias C Corti, M Cobanaj, F Marian, EC Dee, MR Lloyd, S Marcu, ... Cancer Treatment Reviews 108, 102410, 2022 | 43 | 2022 |
| Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial F Conforti, PA Zucali, L Pala, C Catania, V Bagnardi, I Sala, P Della Vigna, ... Lancet Oncology, 2022 | 40 | 2022 |
